Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionKendall Capital Management
Latest Disclosed Ownership2,116 shares
Latest Disclosed Value $ 1,634,617
Kendall Capital Management reports 0.42% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On April 24, 2026 - Kendall Capital Management filed a 13F-HR form disclosing ownership of 2,116 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $1,634,617 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 2,125 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -0.42% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F Regeneron Pharmaceuticals COM 75886F107 2,116 -9 -0.42 1,635 -0.37 0.3350
2026-01-16 2025-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,125 1 0.05 1,640 37.35 0.3431
2025-11-13 2025-09-30 13F Regeneron Pharmaceuticals COM 75886F107 2,124 -4 -0.19 1,194 6.89 0.2693
2025-07-16 2025-06-30 13F Regeneron Pharmaceuticals COM 75886F107 2,128 -84 -3.80 1,117 -20.38 0.2955
2025-04-25 2025-03-31 13F Regeneron Pharmaceuticals COM 75886F107 2,212 -115 -4.94 1,403 -15.33 0.4123
2025-02-07 2024-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,327 -20 -0.85 1,657 -32.81 0.4849
2024-11-08 2024-09-30 13F Regeneron Pharmaceuticals COM 75886F107 2,347 -70 -2.90 2,467 -2.88 0.7616
2024-08-12 2024-06-30 13F Regeneron Pharmaceuticals COM 75886F107 2,417 -70 -2.81 2,540 6.10 0.8469
2024-05-10 2024-03-31 13F Regeneron Pharmaceuticals COM 75886F107 2,487 -210 -7.79 2,393 1.06 0.8234
2024-01-26 2023-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,697 -75 -2.71 2,368 118,300.00 0.9200
2023-10-31 2023-09-30 13F Regeneron Pharmaceuticals COM 75886F107 2,772 -253 -8.36 2 0.00 1.0112
2023-07-28 2023-06-30 13F Regeneron Pharmaceuticals COM 75886F107 3,025 -55 -1.79 2 0.00 0.9525
2023-05-11 2023-03-31 13F Regeneron Pharmaceuticals COM 75886F107 3,080 572 22.81 3 100.00 1.2155
2023-01-30 2022-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,508 -10 -0.40 2 -99.94 0.9141
2022-11-02 2022-09-30 13F Regeneron Pharmaceuticals COM 75886F107 2,518 -9 -0.36 1,735 16.13 1.0096
2022-07-29 2022-06-30 13F Regeneron Pharmaceuticals COM 75886F107 2,527 234 10.20 1,494 -6.68 0.8228
2022-05-06 2022-03-31 13F Regeneron Pharmaceuticals COM 75886F107 2,293 10 0.44 1,601 11.03 0.7738
2022-01-28 2021-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,283 -72 -3.06 1,442 1.19 0.6845
2021-11-05 2021-09-30 13F Regeneron Pharmaceuticals COM 75886F107 2,355 -43 -1.79 1,425 6.42 0.7705
2021-07-30 2021-06-30 13F Regeneron Pharmaceuticals COM 75886F107 2,398 0 0.00 1,339 17.97 0.7528
2021-05-05 2021-03-31 13F Regeneron Pharmaceuticals COM 75886F107 2,398 122 5.36 1,135 3.18 0.7023
2021-02-08 2020-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,276 110 5.08 1,100 -9.24 0.8024
2020-10-22 2020-09-30 13F Regeneron Pharmaceuticals COM 75886F107 2,166 -75 -3.35 1,212 -13.30 1.0543
2020-07-30 2020-06-30 13F Regeneron Pharmaceuticals COM 75886F107 2,241 -70 -3.03 1,398 23.94 1.3389
2020-04-27 2020-03-31 13F Regeneron Pharmaceuticals COM 75886F107 2,311 -165 -6.66 1,128 21.29 1.2764
2020-01-24 2019-12-31 13F Regeneron Pharmaceuticals COM 75886F107 2,476 483 24.23 930 68.17 0.7320
2019-11-12 2019-09-30 13F Regeneron Pharmaceuticals COM 75886F107 1,993 250 14.34 553 1.28 0.4887
2019-08-09 2019-06-30 13F Regeneron Pharmaceuticals COM 75886F107 1,743 414 31.15 546 0.00 0.4939
2019-05-08 2019-03-31 13F Regeneron Pharmaceuticals COM 75886F107 1,329 471 54.90 546 70.63 0.5176
2019-02-13 2018-12-31 13F Regeneron Pharmaceuticals COM 75886F107 858 189 28.25 320 18.52 0.3314
2018-10-29 2018-09-30 13F Regeneron Pharmaceuticals COM 75886F107 669 669 270 0.2298
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.